By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cerus Corporation 

2411 Stanwell Drive

Concord  California  94520   U.S.A.
Phone: 925-288-6000 Fax: 925-288-6001


SEARCH JOBS


Industry
Medical Device


Collaborations

MedImmune 





Company News
FDA Accepts IDE Supplement For Cerus Corporation (CERS)'s INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma 11/21/2014 10:48:05 AM
Cerus Corporation (CERS) Reports Third Quarter 2014 Results 11/5/2014 9:52:15 AM
Cerus Corporation (CERS) Announces Agreement With Kawasumi Laboratories, Inc. For The Development Of INTERCEPT Platelets Kits In Japan 10/29/2014 8:44:24 AM
American Red Cross To Participate In Cerus Corporation (CERS)' IDE Study To Address Chikungunya And Dengue Blood Safety Risks 10/23/2014 10:13:43 AM
Cerus Corporation (CERS) To Release Third Quarter 2014 Results On November 4, 2014 10/22/2014 9:53:20 AM
Cerus Corporation (CERS) Submits Compassionate Use IDE Supplement For INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma 10/20/2014 7:18:26 AM
FDA Accepts IDE Submission By Cerus Corporation (CERS) Making The INTERCEPT Blood System Available To Address Chikungunya And Dengue Blood Safety Risks 10/7/2014 8:22:47 AM
Cerus Corporation (CERS) And Biomedica Foscama Group S.P.A. Enter Distribution Agreement For The INTERCEPT Blood System In Italy 9/11/2014 8:04:51 AM
Cerus Corporation (CERS) Submits IDE Supplement To Make INTERCEPT Platelets Available Pre-Approval In U.S. Areas At Risk From Outbreaks Of Chikungunya And Dengue 9/10/2014 10:50:09 AM
Cerus Corporation (CERS) To Present At The Morgan Stanley (MST) 2014 Global Health Care Conference On September 10, 2014 9/4/2014 10:45:38 AM
12345678910...
//-->